Brief: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
06/09/2024 12:08
Sept 6 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PARTNER JI XING PHARMACEUTICALS LTD ANNOUNCES
POSITIVE
TOPLINE RESULTS FROM THE PHASE 3 STUDY OF ETRIPAMIL IN PSVT IN
CHINA
* MILESTONE PHARMACEUTICALS INC: 500-PATIENT PHASE 3 TRIAL
(JX02002) MET ITS PRIMARY ENDPOINT
Source text for Eikon: ID:nGNX3PmKfs
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview